Stay updated on Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.

Latest updates to the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe page's Locations section was expanded to add numerous locations across the US, Canada, UK, Europe, and Asia, while a number of location entries were removed.SummaryDifference2%

- Check46 days agoChange DetectedAdded revision label v3.3.2 and removed revision label v3.3.1, reflecting a minor admin update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check54 days agoChange DetectedPublications section updated to indicate publications are automatically filled from PubMed and may not be about the study, and the page revision is updated to v3.3.1.SummaryDifference0.0%

- Check61 days agoChange DetectedRemoved the notice about a lapse in government funding and NIH operating status. This notice previously informed users about potential delays and current operations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check75 days agoChange DetectedNo substantial changes to core study details were observed; the page content remains essentially the same with only minor UI adjustments and timestamp updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check104 days agoChange DetectedCore content updated with a funding/operating status notice and a version upgrade from v3.0.2 to v3.2.0; no other substantive content changes detected.SummaryDifference2%

Stay in the know with updates to Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.